Avatrombopag is used to improve the platelet count for people who are having problems with low platelet cells. When using the drug, you need to follow the instructions of your doctor to avoid unwanted side effects.

The drug Maxxhepa urso 200 is used for the gastrointestinal tract. When taking the drug should follow the doctor's prescription to avoid unwanted effects. Here are some sharing about the use of Maxxhepa urso 200.

Ornihepa medicine has the main ingredient L-Ornithine L-Aspartate which is effective in treating liver diseases. To ensure effective use and avoid side effects and drug interactions, patients need to read the instructions carefully and consult a doctor or pharmacist.

The obesity epidemic has led to a dramatic increase in patients with metabolic dysfunction-associated fatty liver disease (MAFLD). While dyslipidemia, type 2 diabetes, and cardiovascular disease guide treatment in patients without evidence of liver fibrosis, liver-related morbidity and mortality become relevant in advanced forms of MAFLD, nonalcoholic steatohepatitis (NASH), and when liver fibrosis develops. Statins should be prescribed for patients without significant fibrosis despite concomitant liver disease but are underused in real-world settings.

Non-alcoholic fatty liver disease (NAFLD) has been recognized as a major cause of chronic liver disease in the industrialized world. The prevalence of NAFLD is not only increased in patients with type 2 diabetes, metabolic syndrome, and obesity, but is also associated with more severe forms of the disease, with a significant proportion of subjects developing NAFLD despite having a relatively normal body mass index (BMI), a condition known as non-obese or lean NAFLD.

The incidence of non-alcoholic fatty liver disease (NAFLD) is significantly increased in people with a relatively normal body mass index (BMI), a condition known as non-obese non-alcoholic fatty liver disease or lean non-alcoholic fatty liver disease. The following article is a review of studies on the prognosis of patients with non-obese non-alcoholic fatty liver disease.